预约演示

更新于：2025-05-07

Liver Abscess, Amebic

阿米巴肝脓肿

更新于：2025-05-07

基本信息

别名

ALA - Amebic liver abscess、ALA - Amoebic liver abscess、Abscess, Amebic Liver

+ [61]

简介

Single or multiple areas of PUS due to infection by any ameboid protozoa (AMEBIASIS). A common form is caused by the ingestion of ENTAMOEBA HISTOLYTICA.

关联

项与阿米巴肝脓肿相关的药物

Ornidazole

奥硝唑

靶点-

作用机制-

在研机构

原研机构

在研适应症

非在研适应症

最高研发阶段批准上市

首次获批国家/地区

中国

首次获批日期2001-01-01

Metronidazole

甲硝唑

靶点-

作用机制

DNA合成抑制剂

在研机构

Baxter Healthcare Corp. [+14]

原研机构

Pfizer Inc.

在研适应症

贾第虫病 [+24]

非在研适应症

复杂腹腔感染 [+5]

最高研发阶段批准上市

首次获批国家/地区

法国

首次获批日期1960-01-01

项与阿米巴肝脓肿相关的临床试验

CTR20220468

/ Active, not recruitingN/A

甲硝唑片在健康受试者中随机、开放、两制剂、单次给药、两周期、双交叉空腹/餐后生物等效性试验

主要目的：以药代动力学参数作为主要终点评价指标，比较口服受试制剂甲硝唑片（生产厂家：江西新赣江药业股份有限公司）与参比制剂甲硝唑片（持证商：Sanofi，商品名：Flagyl®）在健康受试者体内空腹/餐后状态下的药代动力学行为，评价两种制剂在空腹/餐后条件下是否具有生物等效性。次要目的：观察受试制剂甲硝唑片和参比制剂甲硝唑片在健康受试者中的安全性。

开始日期2022-02-21

申办/合作机构

江西新赣江药业股份有限公司

CTR20212653

/ CompletedN/A

奥硝唑片在空腹及餐后条件下的人体生物等效性试验

主要研究目的考察健康受试者在空腹及餐后条件下，单次口服1片由山东鲁抗医药集团赛特有限责任公司生产的奥硝唑片（受试制剂T，规格：0.5g）与相同条件下单次口服1片由OrPha Swiss GmbH持证的奥硝唑片（参比制剂R，商品名：Tiberal®，规格：0.5g）的药动学特征，评价两制剂的生物等效性，为该受试制剂一致性评价提供依据。次要研究目的观察健康受试者在空腹及餐后条件下单次口服0.5g的受试制剂奥硝唑片（规格：0.5g）与参比制剂奥硝唑片（商品名：Tiberal®，规格：0.5g）的安全性。

开始日期2021-10-31

申办/合作机构

山东鲁抗医药集团赛特有限责任公司

CTRI/2021/05/033892

/ RecruitingN/AIIT

Evaluation of efficacy of aspiration in Amebic liver abscess

开始日期2021-06-01

申办/合作机构-

100 项与阿米巴肝脓肿相关的临床结果

登录后查看更多信息

100 项与阿米巴肝脓肿相关的转化医学

登录后查看更多信息

0 项与阿米巴肝脓肿相关的专利（医药）

登录后查看更多信息

2,571

项与阿米巴肝脓肿相关的文献（医药）

2025-06-01·Food and Waterborne Parasitology

Transmission of parasites to people via food: how can we determine their impact and why do we need to know?

Review

作者: Robertson, Lucy J

Foodborne parasites exert a considerable burden on human health, and this can be estimated using the disability-adjusted life year metric, enabling comparisons across regions, age groups, and among parasites and other foodborne hazards. Previous estimates of the burden exerted by different foodborne hazards were published about a decade ago (2015) and an update is planned. These estimates are important, not only for comparative purposes, but also to provide an evidence-based framework for resource allocation for different interventions, including prioritisation of risk management efforts, determining where food safety policy infrastructure should be focused, financing research and innovation, and for targeting supplier and consumer education. Here the potential for improving the previous estimates is discussed, not only by using more recent data, but also by inclusion of foodborne parasitic diseases and disease states that were omitted in the previous estimates. In particular, for example, the inclusion of foodborne infection with Cyclospora cayetensis and with Trypanosoma cruzi are suggested, along with consideration of disease states such as amoebic liver abscess in foodborne amoebiasis. In addition, knowledge gaps, potential interventions, and how intervention effects can be assessed are discussed, using specific examples.

2025-04-01·Turkish Journal of Emergency Medicine

Vascular complications of amebic liver abscess – Computed tomography case series with review of the literature

Article

作者: Arora, Bhavna ; Kakkar, Lovleen ; Mahal, Sachin

Amebiasis is a parasitic infection with amebic liver abscess (ALA) being the most common extraintestinal manifestation. Common complications of ALA include rupture into the pleural, pericardial, or peritoneal cavity. Uncommonly, they can cause vascular complications such as thrombosis of the hepatic vein and inferior vena cava which may further extend to the right atrium or may embolize resulting in pulmonary thromboembolism. In this study, we report three patients with vascular complications in ALA. The presence of vascular pathology in ALAs should not be missed. With its detection and prompt treatment, the progression of vascular complications can be prevented.

2025-03-01·Immunobiology

Toll-like receptor upregulation in liver and peripheral blood mononuclear cells of patients with amoebic liver abscess

Article

作者: Kaur, Upninder ; Duseja, Ajay ; Kalra, Naveen ; Sehgal, Rakesh ; Sharma, Navneet ; Mewara, Abhishek ; Ray, Pallab ; Khunger, Sandhya

AIMWe aimed to understand the host and microbe interactions at the time of infection and inflammatory response in amoebic liver abscess (ALA) patients based on toll-like receptor (TLR) expression (mRNA), cytokine and IgG subtypes levels.METHODS AND RESULTSLiver aspirates from 100 ALA patients and 11 liver autopsy samples were used as negative controls. Blood samples from 100 ALA and 41 healthy individuals were collected. mRNA expression of TLR 1 to 9 genes was measured using reverse transcriptase polymerase chain reaction (RT-PCR). Serum cytokines level was quantified by flow cytometry. In-house ELISA for the analysis of IgG and its subtypes in the serum samples was performed. A total of 7 TLR genes (TLR1, TLR2, TLR4, TLR6, TLR7, TLR8 and TLR9) and 6 TLR genes (TLR1, TLR2, TLR3, TLR4, TLR5 and TLR8) were found to be elevated in liver aspirates and PBMCs respectively. Increased serum cytokine levels were observed in ALA patients vs. healthy controls. Interestingly, a significant increase in IgG and its subtypes (IgG1, IgG3 and IgG4) was found in the serum of ALA patients.CONCLUSIONIncreased levels of TLR, pro- and anti-inflammatory cytokines, IgG and its subtypes, are possibly linked with early-stage infection in ALA patients.IMPACT STATEMENTThe role of TLRs in association with ALA might provide insights into new therapeutic strategies.

分析

对领域进行一次全面的分析。

或

查看完整样例数据

Eureka LS:

全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步

立即开始免费试用!

智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。

立即开始数据试用!

智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。